{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:56:56Z","timestamp":1782867416393,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BTK inhibitors (BTKi) have become standard of care for treatment of patients with chronic lymphocytic leukemia (CLL). Covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib are effective but alterations in the kinase domain at C481 or BTK gatekeeper residue T474 mutations result in development of resistance. Noncovalent BTK inhibitors (ncBTKi) such as pirtobrutinib are effective in patients with C481x mutations developed through use of cBTKi. However, resistance to ncBTKi can occur owing to second site aberrations in\n                    <jats:italic>BTK,<\/jats:italic>\n                    generating novel mutations such as L528x and T316x. Sometimes, CLL cells with double BTK mutations are also observed. These BTK aberrations underscore a need for new inhibitors that target pan-BTK-mutants. We evaluated the efficacy of a new ncBTKi, docirbrutinib (AS-1763), against 14 BTK mutants, including C481S, T474x, and L528x, as well as gatekeeper and kinase domain double mutants, using biochemical assays, cell-line models, and primary CLL lymphocytes. Docirbrutinib potently inhibited BTK autophosphorylation and mutant BTK\u2013driven cell proliferation, with greater effects than ibrutinib and pirtobrutinib against certain mutants. In treatment-na\u00efve and relapsed\/refractory CLL samples, docirbrutinib disrupted B-cell receptor signaling and sensitized cells to apoptosis induced by venetoclax and AZD5991. In a dose-escalation trial (NCT05602363), docirbrutinib decreased CCL3\/CCL4 biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with relapsed\/refractory CLL. These findings establish docirbrutinib as a pan-mutant ncBTKi with potential to improve outcomes for CLL patients, including those with disease resistant to cBTKi and other ncBTKi.\n                  <\/jats:p>","DOI":"10.1038\/s41408-026-01509-8","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:44:46Z","timestamp":1778172286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-3509","authenticated-orcid":false,"given":"Natalia","family":"Timofeeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breana","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0062-674X","authenticated-orcid":false,"given":"Hiroko","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohmoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3157-2824","authenticated-orcid":false,"given":"Kyoko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady I.","family":"Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-2188","authenticated-orcid":false,"given":"Masaaki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:16096.","journal-title":"Nat Rev Dis Prim"},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2:58\u201361.","journal-title":"ChemMedChem"},{"key":"1509_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383:460\u201373.","journal-title":"N Engl J Med"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. Hematol Oncol. 2016;9:21.","journal-title":"Hematol Oncol"},{"key":"1509_CR6","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62:7923\u201340.","journal-title":"J Med Chem"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W, Robak T, Ill\u00e9s \u00c1, Kater AP, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144:1061\u20138.","journal-title":"Blood"},{"key":"1509_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2023-183029","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142:62\u201372.","journal-title":"Blood"},{"key":"1509_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00675-9","volume":"12","author":"B Aslan","year":"2022","unstructured":"Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, et al. Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022;12:80.","journal-title":"Blood Cancer J"},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397:892\u2013901.","journal-title":"Lancet"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389:33\u201344.","journal-title":"N Engl J Med"},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022;6:5589\u201392.","journal-title":"Blood Adv"},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","volume":"35","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Wang Q, Bergl\u00f6f A, Schaafsma GCP, Shi Y, Zhou L, et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021;35:1317\u201329.","journal-title":"Leukemia"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7:1929\u201343.","journal-title":"Blood Adv"},{"key":"1509_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science. 2024;383:eadi5798.","journal-title":"Science"},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MeghanC, Montoya S, Notti RyanQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386:735\u201343.","journal-title":"N Engl J Med"},{"key":"1509_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abg5216","volume":"15","author":"K Dhami","year":"2022","unstructured":"Dhami K, Chakraborty A, Gururaja TL, Cheung LW-K, Sun C, DeAnda F, et al. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. Sci Signal. 2022;15:eabg5216.","journal-title":"Sci Signal"},{"key":"1509_CR18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31:2075\u201384.","journal-title":"Leukemia"},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3705\u201315.","journal-title":"Clin Cancer Res"},{"key":"1509_CR20","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","volume":"5","author":"AP Kater","year":"2021","unstructured":"Kater AP, Slinger E, Cretenet G, Martens AW, Balasubramanian S, Leverson JD, et al. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021;5:5410\u20134.","journal-title":"Blood Adv"},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"},{"key":"1509_CR22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213\u20139.","journal-title":"JAMA Oncol"},{"key":"1509_CR23","unstructured":"Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, et al. Ibrutinib with venetoclax in patients with relapsed\/refractory chronic lymphocytic leukemia: A phase II study. Blood Cancer Discovery. 2026;bcd-25-0345."},{"key":"1509_CR24","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2023","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2023;390:326\u2013337.","journal-title":"N Engl J Med"},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1509_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9:342\u201353.","journal-title":"Cancer Discov"},{"key":"1509_CR28","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1080\/10428190410001723317","volume":"45","author":"JB Johnston","year":"2004","unstructured":"Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X, et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma. 2004;45:2017\u201327.","journal-title":"Leuk Lymphoma"},{"key":"1509_CR29","doi-asserted-by":"crossref","unstructured":"Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol 2023;13.","DOI":"10.3389\/fonc.2023.1226289"},{"key":"1509_CR30","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1111\/febs.13714","volume":"283","author":"KA Sarosiek","year":"2016","unstructured":"Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise. Febs J. 2016;283:3523\u201333.","journal-title":"Febs J"},{"key":"1509_CR31","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","volume":"26","author":"X Yi","year":"2020","unstructured":"Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, et al. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020;26:3856\u201367.","journal-title":"Clin Cancer Res"},{"key":"1509_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27:1351\u201364.","journal-title":"Genes Dev"},{"key":"1509_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen ML, Taneja N, Neininger AC, Wang L, Robertson GL, Riffle SN, et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience. 2020;23:101015.","journal-title":"iScience"},{"key":"1509_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100034","volume":"1","author":"N Timofeeva","year":"2024","unstructured":"Timofeeva N, Jain N, Gandhi V. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice. Blood Neoplasia. 2024;1:100034.","journal-title":"Blood Neoplasia"},{"key":"1509_CR35","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.2024024510","volume":"144","author":"LE Roeker","year":"2024","unstructured":"Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, et al. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial. Blood. 2024;144:1374\u201386.","journal-title":"Blood"},{"key":"1509_CR36","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.1c01279","volume":"64","author":"W Kawahata","year":"2021","unstructured":"Kawahata W, Asami T, Kiyoi T, Irie T, Kashimoto S, Furuichi H, et al. Discovery of AS-1763: a potent, selective, noncovalent, and orally available inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2021;64:14129\u201341.","journal-title":"J Med Chem"},{"key":"1509_CR37","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1182\/blood-2023-182568","volume":"142","author":"N Jain","year":"2023","unstructured":"Jain N, D\u2019Olimpio J, Gillis-Smith A, Lee ST, Shah NN, Pinilla-Ibarz J, et al. Trial in progress: a phase 1b study of AS-1763, an oral, potent and selective noncovalent BTK inhibitor, in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma or non-Hodgkin lymphoma. [Abstr] Blood. 2023;142:3288.","journal-title":"[Abstr] Blood"},{"key":"1509_CR38","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1021\/jm8004527","volume":"51","author":"DA Heerding","year":"2008","unstructured":"Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med Chem. 2008;51:5663\u201379.","journal-title":"Med Chem"},{"key":"1509_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"1509_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","volume":"132","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, et al. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132:1039\u201349.","journal-title":"Blood"},{"key":"1509_CR41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","volume":"8","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. 2018;8:1300\u201315.","journal-title":"Cancer Discov"},{"key":"1509_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Di Paolo","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7:41\u201350.","journal-title":"Nat Chem Biol"},{"key":"1509_CR43","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1021\/bi8019756","volume":"48","author":"L Lin","year":"2009","unstructured":"Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R, et al. Activation loop phosphorylation modulates Bruton\u2019s tyrosine kinase (Btk) kinase domain activity. Biochemistry. 2009;48:2021\u201332.","journal-title":"Biochemistry"},{"key":"1509_CR44","doi-asserted-by":"crossref","unstructured":"Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, et al. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight. 2019;4.","DOI":"10.1172\/jci.insight.127566"},{"key":"1509_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16128-5","volume":"11","author":"DP Duarte","year":"2020","unstructured":"Duarte DP, Lamontanara AJ, La Sala G, Jeong S, Sohn YK, Panjkovich A, et al. Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. Nat Commun. 2020;11:2319.","journal-title":"Nat Commun"},{"key":"1509_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2024-199116","volume":"144","author":"MC Thompson","year":"2024","unstructured":"Thompson MC, Parrondo RD, Frustaci AM, Allan JN, Ghia P, Mocanu I, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CADANCE-101 study. Blood. 2024;144:885.","journal-title":"Blood"},{"key":"1509_CR47","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2024-194839","volume":"144","author":"NN Shah","year":"2024","unstructured":"Shah NN, Omer Z, Collins GP, Forconi F, Danilov A, Byrd JC, et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study. Blood. 2024;144:884.","journal-title":"Blood"},{"key":"1509_CR48","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2022-164772","volume":"140","author":"AR Mato","year":"2022","unstructured":"Mato AR, Wierda WG, Ai WZ, Flinn IW, Tees M, Patel MR, et al. NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. Blood. 2022;140:2329\u201332.","journal-title":"Blood"},{"key":"1509_CR49","doi-asserted-by":"publisher","first-page":"4422.1","DOI":"10.1182\/blood-2024-194009","volume":"144","author":"MT Tees","year":"2024","unstructured":"Tees MT, Bond DA, Khan N, Awan FT, Xu Q, Zhang H, et al. A phase 1 study of AC676, a Novel BTK chimeric degrader, in patients with B-cell malignancies. Blood. 2024;144:4422.1\u20131.","journal-title":"Blood"},{"key":"1509_CR50","doi-asserted-by":"crossref","unstructured":"Salvaris RT, Brennan J, Lewis KL. BTK is the target that keeps on giving: a review of BTK-degrader drug development, clinical data, and future directions in CLL. Cancers. 2025;17.","DOI":"10.3390\/cancers17030557"},{"key":"1509_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.seminhematol.2023.12.004","volume":"61","author":"AF vom Stein","year":"2024","unstructured":"vom Stein AF, Hallek M, Nguyen P-H. Role of the tumor microenvironment in CLL pathogenesis. Semin Hematol. 2024;61:142\u201354.","journal-title":"Semin Hematol"},{"key":"1509_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","volume":"2011","author":"JA Burger","year":"2011","unstructured":"Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology. 2011;2011:96\u2013103.","journal-title":"Hematology"},{"key":"1509_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SS Chen","year":"2016","unstructured":"Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833\u201343.","journal-title":"Leukemia"},{"key":"1509_CR54","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/leu.2016.129","volume":"30","author":"F Cervantes-Gomez","year":"2016","unstructured":"Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton\u2019s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 2016;30:1803\u20134.","journal-title":"Leukemia"},{"key":"1509_CR55","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","volume":"22","author":"CU Niemann","year":"2016","unstructured":"Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study. Clin Cancer Res. 2016;22:1572\u201382.","journal-title":"Clin Cancer Res"},{"key":"1509_CR56","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32:920\u201330.","journal-title":"Leukemia"},{"key":"1509_CR57","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"ArnonP Kater","year":"2022","unstructured":"Kater ArnonP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"1509_CR58","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1021\/acs.jmedchem.4c00643","volume":"67","author":"H Deng","year":"2024","unstructured":"Deng H, Zhang J, Liu L, Zhang H, Han Y, Wu L, et al. Discovery of novel Mcl-1 inhibitors with a 3-substituted-1H-indole-1-yl moiety binding to the P1\u2013P3 pockets to induce apoptosis in acute myeloid leukemia cells. J Medicinal Chem. 2024;67:13925\u201358.","journal-title":"J Medicinal Chem"},{"key":"1509_CR59","doi-asserted-by":"publisher","first-page":"14370","DOI":"10.1021\/acs.jmedchem.4c01188","volume":"67","author":"JC Tarr","year":"2024","unstructured":"Tarr JC, Salovich JM, Aichinger M, Jeon K, Veerasamy N, Sensintaffar JL, et al. Discovery of a myeloid cell leukemia 1 (Mcl-1) inhibitor that demonstrates potent in vivo activities in mouse models of hematological and solid tumors. J Med Chem. 2024;67:14370\u201393.","journal-title":"J Med Chem"},{"key":"1509_CR60","doi-asserted-by":"crossref","unstructured":"Velter IA, Lento W, Peschiulli A, Reuillon TD, Ferrer S, Orgaz-Gordillo S, et al. In pursuit of best-in-class MCL-1 inhibitors: discovery of highly potent 1,4-indoyl macrocycles with favorable physicochemical properties. J Med Chem. 2025.","DOI":"10.1021\/acs.jmedchem.4c03166"},{"key":"1509_CR61","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","volume":"5","author":"U Rauh","year":"2024","unstructured":"Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024;5:1479\u201393.","journal-title":"Nat Cancer"},{"key":"1509_CR62","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1021\/acs.jmedchem.9b00919","volume":"62","author":"Z Wang","year":"2019","unstructured":"Wang Z, He N, Guo Z, Niu C, Song T, Guo Y, et al. Proteolysis targeting chimeras for the selective degradation of Mcl-1\/Bcl-2 derived from nonselective target binding ligands. J Med Chem. 2019;62:8152\u201363.","journal-title":"J Med Chem"},{"key":"1509_CR63","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"1509_CR64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2023-186432","volume":"142","author":"JA Woyach","year":"2023","unstructured":"Woyach JA, Stephens DM, Brander DM, Kittai AS, Hu B, Sitlinger A, et al. Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton\u2019s tyrosine kinase. Blood. 2023;142:328.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01509-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:20:30Z","timestamp":1782865230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01509-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HF, TA, HE, M.H, FN, HO, and YN are full-time employees of Carna Biosciences, Inc., and have no competing interests or conflicts of interest. KM is full-time employee of CarnaBio USA, Inc., and has no competing interests or conflicts of interest. AA is a Chief Development Officer and a Board Member of Carna Biosciences, Inc. MS is a Chief Scientific Officer and a Board Member of Carna Biosciences, Inc. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Live vertebrates were not used in this project. Patients with CLL disease participated in this project. Collection and use of patient samples were obtained by informed consent from each participant and protocol to collect patient samples was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"107"}}